Molecular findings in oral premalignant fields: update on their diagnostic and clinical implications

Oral Diseases

Volumn 18, Issue 1, 2012, Pages 40-47

  Gonzalez Moles, Ma ^a   Scully, C ^b   Ruiz Avila, I ^c  

^a UNIVERSITY OF GRANADA   (Spain)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

Author keywords

Oral cancer; Premalignant fields

Indexed keywords

CYCLOOXYGENASE 2; ETRETIN; KI 67 ANTIGEN; P21 ACTIVATED KINASE; PROTEIN MDM2; PROTEIN P14; PROTEIN P16; PROTEIN P27; PROTEIN P53; PROTEIN P63; PROTEIN P73; VASCULOTROPIN;

ANTIGEN EXPRESSION; CELL CYCLE REGULATION; HUMAN; IMMUNOHISTOCHEMISTRY; LEUKOPLAKIA; LICHEN PLANUS; MOLECULAR PATHOLOGY; MOUTH CAVITY; MOUTH TUMOR; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; OROPHARYNX; PLOIDY; PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR;

CARCINOMA, SQUAMOUS CELL; CELL CYCLE PROTEINS; CHEMOPREVENTION; CHROMOSOME ABERRATIONS; CYTOGENETIC ANALYSIS; EPITHELIUM; HUMANS; KI-67 ANTIGEN; LOSS OF HETEROZYGOSITY; MICROSATELLITE REPEATS; MOLECULAR DIAGNOSTIC TECHNIQUES; MOUTH NEOPLASMS; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, MULTIPLE PRIMARY; NEOPLASMS, SECOND PRIMARY; PRECANCEROUS CONDITIONS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84155162962     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2011.01845.x     Document Type: Review

References (88)

1. Agarwal S, Mathur M, Srivastava A, Ralhan R (1999). MGM2/p53 co expression in oral pre malignant lesions; potential prognostic implications. Oral Oncol 35: 209-216.
2. Bagan JV, Murillo J, Poveda R, Gavaldá C, Jiménez Y, Scully C (2004). Proliferative verrucous leukoplakia: unusual locations of oral squamous cell carcinomas, and field cancerization as shown by the appearance of multiple OSCCs. Oral Oncol 40: 440-443.
3. Bagán JV, Scully C, Jimenez Y, Martorell M (2010). Proliferative verrucous leukoplakia: a concise update. Oral Dis 16: 328-332.
4. Beenken SW, Sellers MT, Huang P (1999). Transforming growth factor alpha (TGF-alpha) expression in dysplastic oral leukoplakia: modulation by 13-cis retinoic acid. Head Neck 21: 566-573.
5. Bilde A, von Buchwald C, Dabelsteen E, Therkildsen MH, Dabelsteen S (2009). Molecular markers in the surgical margin of oral carcinomas. J Oral Pathol Med 38: 72-78.
6. Bongers V, Snow GB, de Vries N et al (1995). Second primary head and neck squamous cell carcinoma predicted by the glutathione S-transferase expression in healthy tissue in the direct vicinity of the first tumor. Lab Invest 73: 503-510.
7. Braakhuis BJ, Tabor MP, Leemans CR, van der Waal I, Snow GB, Brakenhoff RH (2002). Second primary tumors and field cancerization in oral and oropharyngeal cancer: molecular techniques provide new insights and definitions. Head Neck 24: 198-206.
8. Braakhuis B, Leemans C, Brakenhoff R (2004). A genetic progression model of oral cancer: current evidence and clinical implications. J Oral Pathol Med 33: 317-322.
9. Bradley G, Odell EW, Raphael S et al (2010). Abnormal DNA content in oral epithelial dysplasia is associated with increased risk of progression to carcinoma. Br J Cancer 26: 1432-1442.
10. Bremmer JF, Braakhuis BJ, Ruijter-Schippers HJ et al (2005). A non-invasive genetic screening test to detect oral preneoplastic lesions. Lab Invest 85: 1481-1488.
11. Bremmer JF, Braakhuis BJ, Brink A et al (2008). Comparative evaluation of genetic assay to identify oral pre-cancerous field. J Oral Pathol Med 37: 599-606.
12. Brennan JA, Mao L, Hruban RH et al (1995). Molecular assessment of histopathological staging in squamous cell carcinoma of the head and neck. N Engl J Med 332: 429-435.
13. Brinkman B, Wong TW (2006). Disease mechanism of biomarkers of oral squamous cell carcinoma. Curr Opin Oncol 18: 228-233.
14. Califano J, van der Riet P, Westra W et al (1996). Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 56: 2488-2492.
15. Chang KW, Lin SC, Kwan PC, Wong YK (2000). Association of aberrant p53 and p21(WAF1) immunoreactivity with the outcome of oral verrucous leukoplakia in Taiwan. J Oral Pathol Med 29: 56-62.
16. Chen YK, Hsue SS, Lin LM (2005). Expression of p63 protein and mRNA in oral epithelial dysplasia. J Oral Pathol Med 34: 232-239.
17. Chiesa F, Tradati N, Marazza M et al (1993). Fenretinide (4-HPR) in chemoprevention of oral leukoplakia. J Cell Biochem Suppl 17: 255-261.
18. Cruz IB, Snijders PJ, Meijer CJ et al (1998). p53 expression above the basal cell layer in oral mucosa is an early event of malignant transformation and has predictive value for developing oral squamous cell carcinoma. J Pathol 184: 360-368.
19. van Der Meij EH, Mast H, Van Der Waal I (2007). The possible premalignant character of oral lichen planus and oral lichenoid lesions: a prospective five-year follow-up study of 192 patients. Oral Oncol 43: 742-748.
20. van Der Waal I (2010). Potentially malignant disorder of the oral and oropharyngeal mucosa; present concepts of management. Oral Oncol 46: 426-428.
21. Duffey DC, Eversole LR, Abemayor E (1996). Oral lichen planus and its association with squamous cell carcinoma: an update on pathogenesis and treatment implications. Laryngoscope 106: 357-362.
22. Esteban F, Bravo JJ, González Moles MA, Bravo M, Ruiz Ávila I, Gil Montoya JA (2005). Adhesion molecule CD44 as a prognostic factor in laryngeal cancer. Anticancer Res 25: 1115-1122.
23. Gasco M, Crook T (2003). The p53 network in head and neck cancer. Oral Oncol 39: 222-231.
24. González Moles MA, Ruiz Ávila I, Rodriguez Archilla A, Martinez Lara I (2000). Suprabasal expression of ki-67 antigen as a marker of presence and severity of oral epithelial dysplasia. Head Neck 22: 658-661.
25. WAF1/CIP1 protein and tongue cancer prognosis. Anticancer Res 24: 3225-3231.
26. Gonzalez-Moles MA, Bascones-Ilundain C, Gil-Montoya JA, Ruiz-Avila I, Delgado-Rodriguez M, Bascones-Martinez A (2006). Cell cycle regulating mechanisms in oral lichen planus: molecular bases in epithelium predisposed to malignant transformation. Arch Oral Biol 51: 1093-1103.
27. Gonzalez-Moles MA, Scully C, Gil-Montoya JA (2008a). Oral lichen planus: controversies surrounding malignant transformation. Oral Dis 14: 229-243.
28. Gonzalez-Moles MA, Gil-Montoya JA, Ruiz-Avila I, Esteban F, Bascones-Martinez A (2008b). Differences in the expression of p53 protein in oral lichen planus based on the use of monoclonal antibodies DO7 and pAb 240. Oral Oncol 44: 496-503.
29. González-Moles MA, Rodriguez-Archilla A, Ruiz-Avila I, Martínez AB, Morales-Garcia P, González-Moles S (2002). p16 expression in squamous carcinomas of the tongue. Onkologie 25: 433-436.
30. González-Moles MA, Bravo M, Ruiz-Avila I, Esteban F, Bascones-Martínez A, González-Moles S (2004b). Adhesion molecule CD44 expression in non-tumour epithelium adjacent to tongue cancer. Oral Oncol 40: 281-286.
31. González-Moles MA, Bravo M, Ruiz-Ávila I et al (2010). Ki-67 expression in non-tumour epithelium adjacent to oral cancer as risk marker for multiple oral tumours. Oral Dis 16: 68-75.
32. Grandis JR, Tweardy DJ (1993). Elevated levels of transforming growth factor-alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 53: 3579-3584.
33. Hafian H, Venteo L, Sukhanova A, Nabiev I, Lefevre B, Pluot M (2004). Immunohistochemical study of DNA topoisomerase I, DNA topoisomerase II alpha, p53, and Ki-67 in oral preneoplastic lesions and oral squamous cell carcinomas. Hum Pathol 35: 745-751.
34. Hahn WC, Weinberg RA (2002). Mechanism of disease: rules for making human tumor cell. N Engl J Med 347: 1593-1603.
35. Hashibe M, Ritz B, Le A, Gang Li, Sankaranarayan R, Zhang Z (2005). Radiotherapy for oral cancer as a risk factor for second primary cancers. Cancer Lett 220: 185-195.
36. Holmstrup P, Vedtofte P, Reibel J, Stoltze K (2007). Oral premalignant lesions: is a biopsy reliable? J Oral Pathol Med 36: 262-266.
37. Hong WK, Endicott J, Itri LM et al (1986). 13-cis-retinoid acid in the treatment of oral leukoplakia. N Engl J Med 315: 1501-1505.
38. Hong WK, Lippman SM, Itri LM et al (1990). Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 323: 795-801.
39. van Houten VM, Tabor MP, van den Brekel MW et al (2002). Mutated p53 as a molecular marker for the diagnosis of head and neck cancer. J Pathol 198: 476-486.
40. Kannan R, Bijur GN, Mallery SR (1996). Transforming growth factor-alpha over expression in proliferative verrucous leukoplakia and oral squamous cell carcinoma: an immunohistochemical study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 82: 69-74.
41. Kasperts N, Slotman BJ, Leemans CR, Doornaert BR, Langendijk JA (2006). Results of postoperative reirradiation for recurrent or second primary head and neck carcinoma. Cancer 106: 1536-1547.
42. Katayose Y, Kim M, Rakkar AN, Li Z, Cowan KH, Seth P (1997). Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res 15: 5441-5445.
43. Kelloff GJ, Lippman SM, Dannenberg AJ et al (2006). Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer. A plan to move forward. Clin Cancer Res 12: 3661-3697.
44. Khuri FR, Lee JJ, Lippman SM et al (2006). Randomized phase-III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst 98: 441-450.
45. Lim KP, Sharifa H, Lau SH, Teo SH, Cheong SC (2005). Alterations of the p14ARF-p53-MDM2 pathway in oral squamous cell carcinoma. MDM2 overexpression is a common event. Oncol Rep 14: 963.
46. Lippman SM, Hong WK (1989). Second malignant tumors in head and neck squamous cell carcinoma: the overshadowing threat for patients with early-stage disease. Int J Radiat Oncol Biol Phys 17: 691-694.
47. Lo Muzio L, Mignogna MD, Favia G, Procaccini M, Testa NF, Bucci E (1998). The possible association between oral lichen planus and oral squamous cell carcinoma: a clinical evaluation on 14 cases and review of the literature. Oral Oncol 34: 239-246.
48. Lodi G, Porter S (2008). Management of potentially malignant disorders: evidence and critique. J Oral Pathol Med 37: 63-69.
49. Mao L, El-Naggar AK, Papadimitrakopoulou V et al (1998). Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. Natl Cancer Inst 90: 1545-1551.
50. Mignogna MD, Lo Russo L, Fedele S, Ruopo E, Califano L, Lo Mizzio L (2002). Clinical behaviour of malignant transforming oral lichen planus. Eur J Surg Oncol 28: 838-843.
51. Mignogna MD, Fedele S, Lo Russo L, Mignogna C, de Rosa G, Porter SR (2007). Field cancerization in oral lichen planus. Eur J Surg Oncol 33: 383-389.
52. Murti PR, Warnakulasuriya KA, Johnson NW et al (1998). p53 expression in oral precancer as a marker for malignant potential. J Oral Pathol Med 27: 191-196.
53. Nylander K, Coates PJ, Hall PA (2000). Characterization of the expression pattern of p63α and Np63α in benign and malignant oral epithelial lesions. Int J Cancer 87: 368-372.
54. Owens DM, Watt FM (2003). Contribution of stem cells and differentiated cells to epidermal tumours. Nat Rev Cancer 3: 444-451.
55. Papadimitrakopoulou VA, Shin DM, Hong WK (1996). Molecular and cellular biomarkers for field cancerization and multistep process in head and neck tumorigenesis. Cancer Metastasis Rev 15: 53-76.
56. Pelosi G, Pasni F, Oslen Stenholm C (2002). The p63 immuno reactivity in lung cancer. Yet another player in the development of squamous cell carcinoma. J Pathol 98: 100-109.
57. Perez-Losada J, Balmain A (2003). Stem-cell hierarchy in skin cancer. Nat Rev Cancer 3: 434-443.
58. Pitiyage G, Tilakaratne WM, Tavassoli M, Warnakulasuriya S (2009). Molecular markers in oral epithelial dysplasia: review. J Oral Pathol Med 38: 737-752.
59. Poh CF, Zhang L, Anderson DW et al (2006). Fuorescence visualization detection of field alterations in tumor margins of oral cancer patients. Clin Cancer Res 12: 6716-6722.
60. Poveda-Roda R, Bagán JV, Jiménez Soriano Y, Díaz Fernandez JM, Gavaldá Esteve C (2010). Retinoids and proliferative verrucous leukoplakia. A preliminary study. Med Oral Patol Oral Cir Bucal 15: 3-9.
61. Reichart PA, Philipsen HP (2005). Oral erythroplakia: a review. Oral Oncol 41: 551-561.
62. Rennemo E, Zätterström ULF, Evensen J, Boysen M (2009). Reduced risk of head and neck second primary tumors after radiotherapy. Radiother Oncol 93: 559-562.
63. Rosin MP, Califano JA (2010). The epidermal growth factor receptor axis: support a new target for oral premalignancy. Cancer Prev Res (Phila) 3: 397-399.
64. Rusthoven K, Chen C, Raben D, Kavanagh B (2008). Use of external beam radiotherapy is associated with reduced incidence of second primary head and neck cancer: a SEER database analysis. Int J Radiat Oncol Biol Phys 71: 192-198.
65. Sansal I, Sellers WR (2004). The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 22: 2954-2963.
66. Scully C, Beyli M, Ferreiro MC et al (1998). Update on oral lichen planus: etiopathogenesis and management. Crit Rev Oral Biol Med 9: 86-122.
67. Seixas-Silva JA Jr, Richards T, Khuri FR et al (2005). Phase 2 bioadjuvant study of interferon α-2a, isotretinoin, and vitamin E in locally advanced squamous cell carcinoma of the head and neck: long-term follow-up. Arch Otolaryngol Head Neck Surg 131: 304-307.
68. Shah NG, Trivedi TI, Tankshali RA et al (2007). Molecular alterations in oral carcinogenesis: significant risk predictors in malignant transformation and tumor progression. Int J Biol Markers 22: 132-143.
69. Sheikh MS, Shao ZM, Hussain A, Fontana JA (1993). The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma. Cancer Res 53: 3226-3228.
70. Shin DM, Khuri FR, Murphy B et al (2001). Combined interferon-α, 13-cis-retinoic acid, and α-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. J Clin Oncol 19: 3010-3017.
71. Shintani S, Mihara M, Nakahara Y et al (2002). Expression of cell cycle control proteins in normal epithelium, premalignant and malignant lesions of oral cavity. Oral Oncol 38: 235-243.
72. Silverman S Jr, Gorsky M (1997). Proliferative verrucous leukoplakia: a follow up study of 54 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 84: 154-157.
73. Slootweg PJ, Eveson JW (2005). Tumours of the oral cavity and oropharynx: introduction. In: Barnes L, Eveson JW, Reichart P, Sidransky D, eds. Pathology and genetics of head and neck tumours. World Health Organization classification of tumours. WHO press: Geneva, Switzerland, pp. 230-239.
74. Srinivasan M, Jewell SD (2001). Evaluation of TGF-α and EGFR expression in oral leukoplakia and oral submucous fibrosis by quantitative immunohistochemistry. Oral Oncol 61: 284-292.
75. Stich HF, Hornby AP, Mathew B, Sankaranarayanan R, Nair MK (1988). Response of oral leukoplakias to the administration of vitamin A. Cancer Lett 40: 93-101.
76. Sturgis EM, Miller RH (1995). Second primary malignancies in the head and neck cancer patient. Ann Otol Rhinol Laryngol 104: 946-954.
77. Tabor MP, Brakenhoff RH, van Houten VM et al (2001). Persistence of genetically altered fields in head and neck cancer patients: biological and clinical implications. Clin Cancer Res 7: 1523-1532.
78. Tabor MP, van Houten VM, Kummer JA et al (2002). Genetic differences between primary head and neck tumors and metastases depend on mutational status of the p53 gene. Genes Chromosom Cancer 33: 168-177.
79. Tabor MP, Brakenhoff RH, Ruijter-Schippers HJ et al (2003). Comparative molecular and histological grading of epithelial dysplasia of the oral cavity and the oropharynx. J Pathol 199: 354-360.
80. Thode C, Bilde A, von Buchwald C, Dabelsteen E (2010). TP53 mutations in clinically normal mucosa adjacent to oral carcinomas. J Oral Pathol Med 39: 662-666.
81. Torres-Rendon A, Stewart R, Craig GT, Wells M, Speight PM (2009). DNA ploidy analysis by image cytometry helps to identify oral epithelial dysplasias with a high risk of malignant progression. Oral Oncol 45: 468-473.
82. Van Der Waal I, Bree R (2010). Second primary tumor in oral cancer. Oral Oncol 46: 426-428.
83. Van Der Waal I, Reitchart P (2008). Oral proliferative verrucous leukoplakia revisited. Oral Oncol 44: 719-721.
84. Van Zandwijk N, Dalesio O, Pastorino U, De Vries N, Van Tinteren H (2000). EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the European Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J Natl Cancer Inst 92: 977-986.
85. Warnakulasuriya S (2010). Living with oral cancer: epidemiology with particular reference to prevalence and life-style changes that influence survival. Oral Oncol 46: 407-410.
86. Warnakulasuriya KA, Robinson D, Evans H (2003). Multiple primary tumours following head and neck cancer in southern England during 1961-98. J Oral Pathol Med 32: 443-449.
87. Williams HK, Sanders DS, Jankowski JA, Landini G, Brown AM (1998). Expression of cadherins and catenins in oral epithelial dysplasia and squamous cell carcinoma. J Oral Pathol Med 27: 308-317.
88. Wu X, Bayle JH, Olson D, Levine AJ (1993). The p53-mdm-2 autoregulatory feedback loop. Genes Dev 7: 1126-1132.